| Public | TSX:NPC |
| Website | allontherapeutics... |
| Category | BioTech |
| Phone | 604.736.0634 |
| info@allontherape... | |
| Employees |
| TOTAL | $10M |
| FUNDING TOTAL | $10M |
| Venture Round, 3/10 Yorkville Advisors | $10M |
Allon Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs to treat neurodegenerative diseases. Its lead product, Davunetide intranasal, an intranasal drug product, which is in Phase IIa clinical trial for the treatment for Alzheimer’s disease, schizophrenia cognitive impairment, and frontotemporal dementia. The company is also evaluating davunetide intravenous in a Phase IIa clinical trial for patients who had undergone coronary artery bypass surgery; and AL-309, a pre-clinical compound that has demonstrated efficacy in animal models related to neuropathy, Alzheimer’s disease, and fetal alcohol syndrome. It has collaborations with the National Institute of Aging, the Alzheimer’s Disease Cooperative Study, the Institute for the Study of Aging, and the Tel Aviv University. The company was formerly known as Neuro Discovery Inc. and changed its name in September 2004 to Allon Therapeutics Inc. as a result of acquisition of Allon Therapeutics, Inc. The company is headquartered in Vancouver, Canada.
